Phagocytes

Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease and proposes potential treatment pathway with sonlicromanol

Retrieved on: 
Wednesday, April 15, 2020
Branches of biology, Biology, Antivirals, Cytokines, Phagocytes, Cell signaling, Immunology, Macrophage, Interferon, Apoptosis, Antiviral drug

The Khondrion research teams hypothesis that selective mPGES-1 inhibition might reduce COVID-19 associated disease symptoms, e.g.

Key Points: 
  • The Khondrion research teams hypothesis that selective mPGES-1 inhibition might reduce COVID-19 associated disease symptoms, e.g.
  • acute respiratory distress syndrome (ARDS), is based on PGE2s role as an inflammatory modulator in viral infections as well as evidence that targeted PGE2 inhibition enhances antiviral immunity4,5,6.
  • Khondrion research using human fibroblast cells and a mouse macrophage-like cell line shows that sonlicromanol is able to block mPGES-1 and decrease PGE2 production.
  • Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages.

Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer

Retrieved on: 
Thursday, January 9, 2020
Branches of biology, Cell biology, Immune system, Lymphatic system, Macrophage, Phagocytes

Dr. Venkat Reddy, CSO of Macrophage Pharma, commented:"I am excited to join Macrophage Pharma as CSO and look forward to advancing and expanding the Company's unique technology platform , exemplified by a drug candidate on track to enter clinical trials.

Key Points: 
  • Dr. Venkat Reddy, CSO of Macrophage Pharma, commented:"I am excited to join Macrophage Pharma as CSO and look forward to advancing and expanding the Company's unique technology platform , exemplified by a drug candidate on track to enter clinical trials.
  • This novel platform allows us to manipulate macrophage and other immune cell functions with the potential to impact areas of unmet need.
  • As co-originator of the ESMTM technology I am proud of MPL's achievements to date and look forward to working with our enhanced team in support of the further growth and development of Macrophage Pharma."
  • Dr Moffat co-founded MPL in November 2014 and is co-inventor in the discovery and development of the ESMTM technology platform.

Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer

Retrieved on: 
Thursday, January 9, 2020
Branches of biology, Cell biology, Immune system, Lymphatic system, Macrophage, Phagocytes

Dr. Venkat Reddy, CSO of Macrophage Pharma, commented:"I am excited to join Macrophage Pharma as CSO and look forward to advancing and expanding the Company's unique technology platform , exemplified by a drug candidate on track to enter clinical trials.

Key Points: 
  • Dr. Venkat Reddy, CSO of Macrophage Pharma, commented:"I am excited to join Macrophage Pharma as CSO and look forward to advancing and expanding the Company's unique technology platform , exemplified by a drug candidate on track to enter clinical trials.
  • This novel platform allows us to manipulate macrophage and other immune cell functions with the potential to impact areas of unmet need.
  • As co-originator of the ESMTM technology I am proud of MPL's achievements to date and look forward to working with our enhanced team in support of the further growth and development of Macrophage Pharma."
  • Dr Moffat co-founded MPL in November 2014 and is co-inventor in the discovery and development of the ESMTM technology platform.

Macrophage Pharma Announces Appointment of Leading International Scientific Advisory Board

Retrieved on: 
Monday, September 10, 2018
Medicine, Biology, Immune system, Clinical medicine, Cell biology, Macrophages, Phagocytes, Immunotherapy

Macrophage Pharma Limited ('MPL'), a company focused on the discovery and development of next-generation small molecules aiming to modulate immune responses to combat cancer and other diseases, announced today the formation of an international Scientific Advisory Board (SAB).

Key Points: 
  • Macrophage Pharma Limited ('MPL'), a company focused on the discovery and development of next-generation small molecules aiming to modulate immune responses to combat cancer and other diseases, announced today the formation of an international Scientific Advisory Board (SAB).
  • The Scientific Advisory Board will closely work with management team as it seeks to maximise the potential of its proprietary Esterase Sensitive Motif (ESM) platform and evolve Macrophage Pharma into a leading immunotherapy company.
  • On welcoming the members to the SAB, Steven Powell, CEO of Macrophage Pharma, said: "We are delighted to have attracted this stellar group of experts to our Advisory Board.
  • Macrophage Pharma is developing a highly novel class of small molecule therapeutics which modulate immune responses to combat disease based on its proprietary Esterase Motif Technology (ESM) platform.

European Hematology Association: Iron: a double-edged Sword in Inflammation

Retrieved on: 
Friday, June 15, 2018
Biology, Medicine, Physiology, Macrophages, Immune system, Lymphatic system, Phagocytes, Inflammation, Human iron metabolism, Red blood cell, Iron deficiency, Anemia

Therefore macrophages are essential both for iron metabolism and protection from infections.

Key Points: 
  • Therefore macrophages are essential both for iron metabolism and protection from infections.
  • The focus of our research was to study whether iron accumulation in these three different pathologic conditions causes macrophage inflammation and the production of inflammatory molecules and analyze the consequences.
  • This effect causes chronic inflammation and tissue damage in sickle patients and patients treated with iron.
  • We conclude that different forms of iron accumulation in macrophages (RBCs versus free heme and iron) in different diseases, show opposite effects on inflammation.

Old bones can heal with proper signals: Targeting macrophages to stimulate osteoblasts

Retrieved on: 
Thursday, May 24, 2018
Macrophages, Biology, Immune system, Immunology, Cell biology, Phagocytes, LRP1, Lipoprotein receptor-related protein, Adipose tissue macrophages, Pancreatic islet macrophage

Baht and colleagues have determined that M2 macrophages, a macrophage phenotype associated with repair and reduction of inflammation, are important in fracture healing.

Key Points: 
  • Baht and colleagues have determined that M2 macrophages, a macrophage phenotype associated with repair and reduction of inflammation, are important in fracture healing.
  • Through mass spectrometry studies, a list of 'youth factors' and 'aging factors' associated with M2 macrophages were identified.
  • One of the factors, low-density lipoprotein receptor-related protein 1 (LRP1), stood out as a potential candidate to improve fracture repair.
  • Bone marrow cells from young control and LRP1 knockout mice were transplanted into old mice that had previously been irradiated.

Forty Seven Inc. Appoints Ian T. Clark to Board of Directors

Retrieved on: 
Monday, April 30, 2018
Biology, Immunology, Cell biology, Immune system, Macrophages, Phagocytes, Medicine, Cancer immunotherapy

MENLO PARK, Calif., April 30, 2018 /PRNewswire/ --Forty Seven Inc., a clinical-stage company focused on developing checkpoint therapies to activate macrophages in the fight against cancer, today announced the appointment of Ian T. Clark to its board of directors.

Key Points: 
  • MENLO PARK, Calif., April 30, 2018 /PRNewswire/ --Forty Seven Inc., a clinical-stage company focused on developing checkpoint therapies to activate macrophages in the fight against cancer, today announced the appointment of Ian T. Clark to its board of directors.
  • We look forward to his insights and are pleased to welcome him to the Board."
  • Mr. Clark currently serves on the boards of Agios Pharmaceuticals, Corvus Pharmaceuticals, Shire Pharmaceuticals, the Gladstone Foundation and he previously served on the board of the Biotechnology Industry Organization (BIO).
  • "By harnessing the power of macrophages to fight cancer, Forty Seven is pioneering a new approach to immuno-oncology, with the potential to transform the treatment of cancer," said Ian Clark.